Requip Xl

(Ropinirole Hydrochloride)

PreclinicalSmall molecule

GGlaxo Dba Glaxosmithkline

Requip Xl is one of 60 small molecule programs targeting Single Dose. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Single DoseCompleted

TreatmentCompleted

Single DosePreclinical

Completed

TreatmentPreclinical

Completed

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Biltricide

Bayer

Preclinical

4 2

Lamprene

Novartis

Preclinical

1 3

Emtriva

Gilead

Preclinical

1 4

Alfenta

Jazz Pharmaceuticals

Preclinical

1 5

Niclocide

Bayer

Preclinical

1 6

Minipress

Pfizer

Preclinical

1 7

Valium

Akero Therapeutics

Preclinical

2 8

Sirturo

WWim Janssens

Preclinical

1 9

Aurlumyn

BBTG International Inc.

Preclinical

1 10

Intuniv

PPromius Pharma, LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Treatment1 trial

A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions

Completed·RRoxane Laboratories·N/A·NCT00674310·29 enrolled

Single Dose1 trial

A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions

Completed·RRoxane Laboratories·N/A·NCT00673088·30 enrolled

Parkinson's Disease1 trial

Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease

Unknown status·—·Phase 3·NCT00260793·20 enrolled

Regulatory

FDA Approval Timeline[4]

Sep 19, 1997

REQUIP

NDA NDA020658

Jun 13, 2008

REQUIP XL

NDA NDA022008

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Ropinirole Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ropinirole Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ropinirole Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA022008). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Glaxo Dba Glaxosmithkline company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGlaxo Dba Glaxosmithkline

Requip Xl

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Treatment1 trial

Single Dose1 trial

Parkinson's Disease1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News